Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14551133 | 0.89 | MTNR1B (0.51) | MTNR1BNPC1KDM4EALDH1A1HTR6 | |
| SCHEMBL12519401 | 0.88 | MTNR1B (0.50) | MTNR1BNPC1KDM4EALDH1A1HTR6 | |
| SCHEMBL12726156 | 0.88 | KMT2A (0.52) | MTNR1BNPC1KDM4EALDH1A1MEN1 | |
| SCHEMBL11021480 | 0.86 | MTNR1B (0.48) | MTNR1BNPC1KDM4EALDH1A1HTR6 | |
| SCHEMBL2217484 | 0.85 | KDM4E (0.55) | NPC1KDM4EALDH1A1RECQLLMNA | |
| SCHEMBL21538245 | 0.79 | KDM4E (0.67) | NPC1KDM4EALDH1A1HTR6MEN1 | |
| SCHEMBL5178312 | 0.78 | BACE1 (0.57) | KDM4EALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL3454127 | 0.77 | HDAC3 (0.56) | KDM4EALDH1A1HTR6KMT2ALMNA | |
| SCHEMBL12726159 | 0.77 | L3MBTL1 (0.55) | MTNR1BKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL687106 | 0.76 | KDM4E (0.53) | NPC1KDM4EALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085261-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SHH, SMO, GLI1 | MTNR1B 1300/4885NPC1 349/4885KDM4E 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.